← Leaderboards
Jane X Kelly
Portland Va Medical Center
$6,800,762
Attributed
$13,528,090
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,528,090 · 5
VA$0 · 1
By mechanism
R01$12,593,894 · 4
RC1$934,196 · 1
I01$0 · 1
Top collaborators
- Papireddy Kancharla6 shared
- Alison Roth4 shared
- Alison Elizabeth Roth4 shared
- Victor Melendez3 shared
- Kevin A Reynolds3 shared
- Mara Kreishman-Deitrick1 shared
- Maj Brandon Pybus1 shared
- Lisa Read1 shared
Most similar at Portland Va Medical Center
Same institution · by research overlap
- Michael Kevin Riscoe$14,982,665
Others in their field
Top investigators on “Drug Kinetics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$241,865,009
- Sharon A Nachman · Johns Hopkins University$194,646,762
- Carol Nesel · Westat$147,274,423
- Barbara Driver · Westat, Inc.$103,746,400
- Ronald T Mitsuyasu · University Of California Los Angeles$99,239,507
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,714,869
Research focus
Drug KineticsIsoenzymesPermeabilitySafetyPharmaceutical PreparationsPlasmodium FalciparumMetabolicParasitesIterative DesignRodentIn VitroMalariaDrug InteractionsToxic EffectCytochrome P450Chemical SynthesisInfectionDrug ResistanceBloodIn VivoToxicity TestsPlasmodium YoeliiPreventPlasmodium
Grant awards (25)
Novel Multiple-Stage Active Antimalarials$681,816
R01 · FY2025 · AI
Second-Generation Novel Liver Stage Active Antimalarials$659,657
R01 · FY2025 · AI · contact PI
Natural Product Inspired Novel Antimalarials with Radical Cure Potential$618,729
R01 · FY2025 · AI
Novel Synergistic Antimalarials with Resistance Reversal Function$0
I01 · FY2025 · VA · contact PI
Second-Generation Novel Liver Stage Active Antimalarials$659,657
R01 · FY2024 · AI · contact PI
Natural Product Inspired Novel Antimalarials with Radical Cure Potential$625,296
R01 · FY2024 · AI
Novel Synergistic Antimalarials with Resistance Reversal Function$0
I01 · FY2024 · VA · contact PI
Second-Generation Novel Liver Stage Active Antimalarials$659,657
R01 · FY2023 · AI · contact PI
Natural Product Inspired Novel Antimalarials with Radical Cure Potential$656,445
R01 · FY2023 · AI
Novel Multiple-Stage Active Antimalarials$602,825
R01 · FY2023 · AI · contact PI
Novel Synergistic Antimalarials with Resistance Reversal Function$0
I01 · FY2023 · VA · contact PI
Second-Generation Novel Liver Stage Active Antimalarials$659,657
R01 · FY2022 · AI · contact PI
Novel Multiple-Stage Active Antimalarials$616,270
R01 · FY2022 · AI · contact PI
Novel Synergistic Antimalarials with Resistance Reversal Function$0
I01 · FY2022 · VA · contact PI
Second-Generation Novel Liver Stage Active Antimalarials$681,482
R01 · FY2021 · AI · contact PI
Novel Multiple-Stage Active Antimalarials$620,053
R01 · FY2021 · AI
Novel Multiple-Stage Active Antimalarials$637,460
R01 · FY2020 · AI
Novel Multiple-Stage Active Antimalarials$675,318
R01 · FY2019 · AI
Novel Broad-spectrum Antimalarials$715,099
R01 · FY2016 · AI · contact PI
Novel Broad-spectrum Antimalarials$707,637
R01 · FY2015 · AI · contact PI
Novel Broad-spectrum Antimalarials$703,272
R01 · FY2014 · AI · contact PI
Novel Broad-spectrum Antimalarials$665,081
R01 · FY2013 · AI · contact PI
Novel Broad-spectrum Antimalarials$748,483
R01 · FY2012 · AI · contact PI
Dual Function Acridones as A New Antimalarial Chemotype$457,230
RC1 · FY2010 · AI · contact PI
Dual Function Acridones as A New Antimalarial Chemotype$476,966
RC1 · FY2009 · AI · contact PI